Please enable JavaScript.
Coggle requires JavaScript to display documents.
Multiple Sclerosis (MS), References - Coggle Diagram
Multiple Sclerosis (MS)
-
-
Incidence/prevalence
Prevalence
The National MS society study also estimates that nearly 2.3 million people live with Multiple Sclerosis globally
Recent findings from a National MS Society estimate approximately 1 million people in the US are living with Multiple Sclerosis (more than double the last reported number)
The National MS society states that nearly 2000 cases of MS are diagnosed each week in the Unites States
Northern States:
-rates of MS are higher further from the equator
-The rate of MS in Northern states (above the 37th parallel) is twice as high, at about 110-140 cases per 100,000 people
Southern States:
-In southern states (below the 37th parallel) the rate of MS is between 57-78 cases per 100,000 people
Age groups
-
The onset of MS usually occurs between the ages 20-40, but can technically occur at any point of one's life
-
Incidence
About 15% of people who have Multiple sclerosis have one or more family members who have also had MS
The incidence of MS is higher in colder climates.
-People originating from Northern Europe have the highest risk of developing MS, no matter where they move to.
Statistically speaking, far more women have MS than men. The National MS Society estimates Multiple Sclerosis is 2-3 times more common in women than in men.
Clinical Manifestations
-
-Pediatric MS is defined as the appearance of Multiple Sclerosis before the age of 16
-Only 4-5% of MS cases are considered pediatric
Manifestations are similar to those of adults, however optic neuritis, symptoms of encephalopathy like headache, seizures, vomiting, and altered consciousness are more common in pediatric cases.
Diagnostics
No specific tests for MS exist. However, your health care provider will try and rule out other conditions that might manifest similar signs and symtpoms of MS. This is known as a differential diagnosis.
-
Treatments
For relapsing-remitting MS
-MS in which patients have relapses of MS symptoms accompanied by periods of stability
-
Infusion Treatment
Natalizumab (Tysabri)
Designed to block the movement of potentially damaging immune cells from your bloodstream to your brain and spinal cord
Alemtuzumab (Campath, lemtrada)
Helps to reduce relapses of MS by targeting a protein on the surface of immune cells and depleting white blood cells.
Ocrelizumab (Ocrevus)
-Approved to treat both primary and relapsing MS
-designed to reduce relapse rate and slow progression in both forms
-
-
-
-
-
-
-